Table 2. Summary of efficacy (N = 300 patients).

Study	Treatment	DCR	RR	CR	PR	SD	Median PFS (mo)	Median OS (mo)
Siegel 2008 [15]	Bevacizumab	30 (65.0%)	6 (13.0%)	1 (2.2%)	5 (10.9%)	24 (52.0%)	6.9	12.4
Hsu 2010 [16]	Bevacizumab/capecitabine	23 (51.1%)	4 (8.9%)	0 (0%)	4 (8.9%)	19 (42.2%)	2.7	5.9
Sun 2011 [17]	Bevacizumab/CAPOX	31 (77.5%)	8 (20.0%)	0 (0%)	8 (20.0%)	23 (57.5%)	6.8	9.8
Kaseb 2012 [18]	Bevacizumab/erlotinib	47 (79.6%)	14 (23.7%)	0 (0%)	14 (23.7%)	33 (55.9%)	7.2	13.7
Thomas 2009 [19]	Bevacizumab/erlotinib	27 (67.5%)	10 (25.0%)	0 (0%)	10 (25.0%)	17 (42.5%)	9.0	15.7
Yau 2012 [20]	Bevacizumab/erlotinib	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1.5	4.4
Philip 2012 [21]	Bevacizumab/erlotinib	12 (44.4%)	1 (2.1%)	0 (0%)	1 (2.1%)	11 (40.7%)	3.0	9.5
Zhu 2006 [22]	Bevacizumab/GEMOX	14 (42.0%)	6 (18.0%)	0 (0%)	6 (18.0%)	8 (24.0%)	5.3	9.6

DCR: Disease control rate (CR+PR+SD); RR: Response rate (CR+PR); CR: Complete response; PR: Partial response; SD: Stable disease; PFS: Progression-free survival; OS: Overall survival; CAPOX: Capecitabine+oxaliplatin; GEMOX: Gemcitabine+oxaliplatin; mo: months.